Should CAR-T Cell Therapy Be Considered a Standard of Care for Patients with Refractory Diffuse Large B-cell Lymphoma in Second Line Treatment?
EXPERT OPINION ON BIOLOGICAL THERAPY（2025）
Key words
CAR-T cell,diffuse large B cell lymphoma,Naive T-cells,second line,systemic inflammation,T-cell fitness,tumor microenvironment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined